Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 1.00 |
| ▸ | FABP5 | Q01469 | 3/20 | 1.00 |
| ▸ | FABP3 | P05413 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | FNTA | P49354 | 2/20 | 0.57 |
| ▸ | FNTB | P49356 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30549325 | 1.00 | FABP4 (1.00) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL27763456 | 0.98 | FABP4 (0.96) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL4314440 | 0.89 | FABP4 (1.00) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL30573159 | 0.89 | FABP4 (1.00) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL16468649 | 0.87 | FABP4 (0.76) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL12951764 | 0.87 | FABP4 (1.00) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL16156852 | 0.86 | FABP4 (0.73) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL3318737 | 0.86 | FABP4 (0.73) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL1120329 | 0.86 | FABP4 (0.73) | FABP4FABP5FABP3KDM4EALDH1A1 | |
| SCHEMBL17482066 | 0.86 | FABP4 (0.73) | FABP4FABP5FABP3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | claimed |
| US-20100171923-A1 | LACTAM POLYMER DERIVATIVES | JOHSNON & JOHNSON VISION CARE, INC. | 2010-07-08 | — | — | US | claimed |
| EP-2107908-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | Redpoint Bio Corporation (US) | 2009-10-14 | — | — | EP | claimed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | claimed |
| WO-2008097504-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | REDPOINT BIO CORPORATION (US) | 2008-08-14 | — | — | WO | claimed |
| US-20070290174-A1 | LACTAM POLYMER DERIVATIVES | JOHNSON & JOHNSON VISION CARE, INC. | 2007-12-20 | — | — | US | claimed |
| EP-1799724-A2 | LACTAM POLYMER DERIVATIVES | Johnson and Johnson Vision Care, Inc. (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006039276-A2 | LACTAM POLYMER DERIVATIVES | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| US-20060069235-A1 | Lactam polymer derivatives | JOHNSON & JOHNSON VISION CARE, INC. | 2006-03-30 | — | — | US | claimed |
| CN-116554126-A | Compound for targeted degradation of CDK6 and application thereof | 兰州大学 | 2023-08-08 | — | — | CN | disclosed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-11402560-B2 | Method for producing laminated body | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-08-02 | — | — | US | disclosed |
| CN-109154686-B | Resin laminate with polarizing plate and display device comprising same | 住友化学株式会社 | 2021-12-24 | — | — | CN | disclosed |
| CN-112771421-A | Polarizing plate composite and image display device | 住友化学株式会社 | 2021-05-07 | — | — | CN | disclosed |
| US-5468757-A | FOR TREATING STROKE OR MYOCARDIAL INFARCTION IN HUMANS | ELI LILLY AND COMPANY (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0668279-A2 | 6-Azaindole thromboxane synthase inhibitors | ELI LILLY AND COMPANY (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0667347-A1 | Beta-carboline thromboxane synthase inhibitors | ELI LILLY AND COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0665227-A1 | Polyhydronorharman synthase inhibitors | ELI LILLY AND COMPANY (US) | 1995-08-02 | — | — | EP | disclosed |
| WO-1995002408-A1 | COMBINATION OF A PROGESTATIONAL AGENT AND A NITRIC OXIDE SYNTHASE SUBSTRATE AND/OR DONOR FOR THE TREATMENT OF PREECLAMPSIA AND PRETERM LABOR | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994022898-A1 | NEW GLUCOCORTICOIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | FABP4 136/4885FABP5 46/4885FABP3 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.